Original Research Article

Adjuvant Chemotherapy after Neoadjuvant Chemotherapy and Long-term Outcomes of CAPOX Plus Bevacizumab Followed by TME for High-risk Localized Rectal Cancer

Junichi Nishimura1, Junichi Hasegawa2, Shingo Noura2, Kimimasa Ikeda3, Masayoshi Yasui4, Takamichi Komori4, Masaki Tsujie5, Keigo Yasumasu6, Tatsushi Shingai7, Mamoru Uemura8, Taishi Hata8, Chu Matsuda9, Tsunekazu Mizushima10, Masataka Ikeda1, Yuichiro Doki8 and Masaki Mori10

1) Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan
2) Department of Surgery, Osaka Rosai Hospital, Sakai, Japan
3) Department of Surgery, Minoh City Hospital, Minoh, Japan
4) Department of Surgery, Osaka General Medical Center, Osaka, Japan
5) Department of Surgery, Sakai City Medical Center, Sakai, Japan
6) Department of Surgery, JCHO Osaka Hospital, Osaka, Japan
7) Department of Surgery, Saiseikai Senri Hospital, Suita, Japan
8) Department of Gastroenterological Surgery, Osaka University, Suita, Japan
9) Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan
10) Department of Surgery and Science, Kyushu University, Fukuoka, Japan

Abstract
Objectives: We previously reported the feasibility of neoadjuvant capecitabine and oxaliplatin plus bevacizumab as a treatment for locally advanced rectal cancer (UMIN000003219). The aim of this study is to investigate the prognostic relevance of neoadjuvant chemotherapy followed by total mesorectal resection (TME).

Methods: Twenty-five patients of our prior multicenter prospective study of neoadjuvant chemotherapy followed by TME enrolled to this study. We analyzed the adjuvant chemotherapy regimen, and the duration between surgery and initial chemotherapy treatment. Five-year progression-free survival and overall survival were estimated using the Kaplan-Meier method.

Results: Among survivors, the median follow-up time was 66 months. Recurrence occurred in six patients, all of whom had suboptimal tumor regression after neoadjuvant chemotherapy. Five patients died from other causes. The rate of local recurrence and distant metastasis was 17.4% and 8.7%, respectively. Five-year progression-free survival was 70.0%, and 5 year overall survival was 84.0%.

Conclusions: We report the long-term survival of patients who received neoadjuvant chemotherapy without radiation followed by TME, revealing a generally favorable prognosis.

Keywords
rectal cancer, neoadjuvant chemotherapy, long-term survival, CapeOX, bevacizumab

J Anus Rectum Colon 2020; 4(3): 108-113
Introduction

Locally advanced rectal cancer has a poor prognosis and constitutes a substantial health problem. In Western countries, the standard treatment is preoperative chemoradiation therapy (CRT) combined with total mesorectal excision (TME), which has been evaluated in several clinical studies. In Japan, the current standard treatment for locally advanced rectal cancer is TME or tumor-specific mesorectal excision (TSME) followed by adjuvant chemotherapy (CTx).

In recent years, there have been advancements in CTx methods for colorectal cancer, including new anticancer agents and targeted biological drugs. Several current guidelines indicate that the best adjuvant chemotherapy regimen includes oxaliplatin and fluoropyrimidine-based chemotherapy. We previously reported the feasibility of administering CAPOX + bevacizumab (BV) as treatment for high-risk localized rectal cancer[1]. In recent years, several clinical trials have demonstrated the efficacy of oxaliplatin-based chemotherapy without RT for locally advanced rectal cancer[2-5]. However, few reports have examined postoperative treatment including adjuvant chemotherapy and long-term survival[6].

In our present study, we assessed the long-term treatment outcomes of patients with locally advanced rectal cancer who were treated with preoperative CAPOX + BV without radiation.

Methods

The primary goal of this study was to update survival data from our previous investigation[1]. This study was approved by the ethics committees at each involved institution and was conducted in accordance with the declaration of Helsinki and all of its amendments, with the aim of offering the greatest protection to the patients.

Patients and treatment

Eligible patients were 20 to 75 years of age and had resectable T4 rectal cancer or nodes positive on magnetic resonance imaging. The protocol of patient treatment was described in the previous report[1]. In brief, patients received CAPOX + BV neoadjuvant CTx before undergoing surgery. Neoadjuvant CTx was administered for four cycles, with the fourth cycle of therapy excluding BV. Our previous study enrolled 25 cases, including 23 patients treated with TME/TSME (UMIN000003219). We defined pCR and near-pCR as we described before[1]. In brief, the complete absence of viable tumor cells in the resected specimen (100% response rate) was defined as a pathological complete response (pCR), and a response rate of ≥95% that was not a pCR was defined as a near-complete response (near-pCR). pCR and near-pCR were defined as favorable tumor regression[7]. After surgery, the decision of whether to administer adjuvant CTx was made by the attending physician in the previous study. For our present study, we recorded each patient’s chemotherapy regimen, duration between surgery and chemotherapy, duration of oxaliplatin treatment, and any adverse events during adjuvant chemotherapy. Patients were evaluated and assessed for relapse every 6 months for approximately 5 years or until death.

Statistical analysis

We performed per-protocol analysis. Categorical variables were described using frequencies. Living patients were censored at last follow-up. Overall survival (OS) was calculated from the date of enrollment to the date of death from any cause, and progression-free survival (PFS) was defined as the time from surgery to relapse. The Kaplan-Meier method was used to estimate time-to-event endpoints.

Adjuvant chemotherapy

Of the 25 patients in our previous study, 23 underwent curative resection. This group had a median age of 63 years (range, 37-75 years) and included 16 male and 7 female patients (Table 1). Lateral lymph node dissection was performed by unilateral in three patients and bilateral in seven patients. The ypStage was stage 0 (pCR) in one patient, stage I in four patients, stage IIA in nine patients, stage IIB in two patients, stage IIC in one patient, stage IIIA in one patient, stage IIIB in three patients, and stage IIIC in one patient. The demographic and clinicopathological characteristics of the patients at baseline and before surgery was described before[1].

Twelve patients (52.2%) received adjuvant chemotherapy (Table 2), with the chemotherapy regimen being CAPOX in 10 patients, capecitabine in one patient, and UFT/LV in one patient. The ypStage who received adjuvant chemotherapy was stage 0 (pCR) in one patient, stage I in three patients, stage IIA in four patients, stage IIB in one patient, and stage IIIB in two patients. Patients who did not receive adjuvant chemotherapy were rejected by 10 patients and StageI by one patient. The median duration from surgery to adjuvant chemotherapy was 57 days (range, 30-68 days). All adjuvant chemotherapy regimens were planned to last 3 months. One patient who underwent CAPOX therapy received three courses of adjuvant chemotherapy and refused one more course, such that the rate of completion of adjuvant chemotherapy with the CAPOX regimen was 90% (nine patients of 10) and 39.1% in all patients (nine patients of 23 patients). We assessed adverse events occurring during adjuvant chemotherapy. No patient who received adjuvant chemotherapy experienced any grade 4 adverse events. The major adverse
Table 1. Patient Background Data.

| No. of patients | 23 |
|-----------------|----|
| Age, years      |    |
| Median          | 63 |
| Range           | 37-75 |
| Sex, n (%)      |    |
| Male            | 16 (69.6) |
| Female          | 7 (30.4) |
| ypStage         |    |
| 0 (pCR)         | 1 (4.3) |
| I               | 4 (17.4) |
| IIA             | 9 (39.1) |
| IIB             | 2 (8.7) |
| IIC             | 1 (4.3) |
| IIIA            | 1 (4.3) |
| IIIB            | 3 (13.0) |
| IIIC            | 1 (4.3) |

Table 2. Adjuvant Chemotherapy.

| Adjuvant chemotherapy | Yes | 12 |
|-----------------------|-----|----|
| ypStage I             | 1   |    |
| ypStage IIA           | 5   |    |
| ypStage IIB           | 2   |    |
| ypStage IIC           | 1   |    |
| ypStageIIIA           | 1   |    |
| ypStageIIIB           | 1   |    |
| ypStageIIIC           | 1   |    |
| No                    | 11  |    |
| ypStage0 (pCR)        | 1   |    |
| ypStageI             | 3   |    |
| ypStageIIA           | 4   |    |
| ypStageIIB           | 1   |    |
| ypStageIIIB          | 2   |    |

Chemotherapy regimen
CAPEOX 10
Capecitabine 1
UFT/LV 1

Days between surgery and chemotherapy 57 (range, 40-68)
CAPOX completion rate 43.5%

Table 3. Adverse Events during Adjuvant Chemotherapy.

| Adverse events (n = 12) | All grades n (%) | G3 n (%) |
|------------------------|------------------|----------|
| Hematologic            |                  |          |
| Neutropenia            | 7 (58.3)         | 4 (33.3) |
| Thrombocytopenia       | 4 (33.3)         | 1 (8.3)  |
| CPK increase           | 1 (8.3)          | 1 (8.3)  |
| Bilirubin increase     | 1 (8.3)          |          |

| Non-hematologic       |                |          |
| Peripheral neuropathy | 4 (33.3)       | 3 (25.0) |
| Hand-foot syndrome    | 4 (33.3)       | 3 (25.0) |
| Malaise               | 3 (25.0)       |          |
| Nausea                | 1 (8.3)        |          |
| Anorexia              | 1 (8.3)        |          |
| Dysgeusia             | 1 (8.3)        |          |

Table 4. Prognosis of Patients.

| Follow-up period among survivors, median (range) |
|-------------------------------------------------|
| 66 months (58-79 months)                        |
| Recurrence site (Include duplicates)           |
| Local*                                          |
| Distant lymph node                              |
| Lung                                            |
| Liver                                           |
| Death                                           |
| Other disease                                   |
|------------------------------------------------|
| All grades n (%) G2 n (%)                       |
|------------------------------------------------|

* Include one duplication of Local and Distant lymph node

remaining 18 patients with suboptimal tumor regression, six patients (33%) experienced recurrence (26.1%), including local recurrence in one patient, lateral lymph node recurrence in two patients, multiple lymph node recurrence in one patient, lung metastasis in one patient, and liver metastasis in one patient. All relapses occurred within 2 years. Of the six patients who suffered recurrence, four had received surgical complete resection, and these four patients achieved a tumor-free condition after reoperation (Table 6). One patient who suffered lateral lymph node recurrence progressed to multiple lymph node recurrence including paraaortic lymph node recurrence. The patients who suffered only lateral lymph node dissection had not received lateral lymph node dissection at primary resection. Three patients died during the study period, including one death from cerebral hemorrhage, one from cardiovascular events, and one from primary lung cancer. To date, no deaths have occurred due to the original disease. Figure 1 shows the Kaplan-Meier curve of PFS and OS in the 25 patients who enrolled the previous study. Five year PFS was 70.0%, and 5 year OS was 84.0%.

PFS and OS

The median follow-up time among the survivors was 66 months, with a range of 58-79 months (Table 4). Five patients exhibited favorable tumor regression, with histopathological findings indicating pCR or near-pCR, and none of these patients experienced recurrence (Table 5). Of the remaining 18 patients with suboptimal tumor regression, six patients (33%) experienced recurrence (26.1%), including local recurrence in one patient, lateral lymph node recurrence in two patients, multiple lymph node recurrence in one patient, lung metastasis in one patient, and liver metastasis in one patient. All relapses occurred within 2 years. Of the six patients who suffered recurrence, four had received surgical complete resection, and these four patients achieved a tumor-free condition after reoperation (Table 6). One patient who suffered lateral lymph node recurrence progressed to multiple lymph node recurrence including paraaortic lymph node recurrence. The patients who suffered only lateral lymph node dissection had not received lateral lymph node dissection at primary resection. Three patients died during the study period, including one death from cerebral hemorrhage, one from cardiovascular events, and one from primary lung cancer. To date, no deaths have occurred due to the original disease. Figure 1 shows the Kaplan-Meier curve of PFS and OS in the 25 patients who enrolled the previous study. Five year PFS was 70.0%, and 5 year OS was 84.0%.
Here, we report the postoperative treatment after curative resection and long-term survival among patients with locally advanced rectal cancer who received neoadjuvant chemotherapy. Nearly half of patients underwent adjuvant chemotherapy. Patients who received 3 months of adjuvant chemotherapy underwent a total of 6 months of chemotherapy, whereas patients who did not receive adjuvant chemotherapy underwent a total of 3 months of chemotherapy including oxaliplatin and BV. Among the 10 patients treated with the CAPOX regimen, nine (90%) completed the planned treatment in full.

There are several advantages of neoadjuvant chemotherapy treatment. Neoadjuvant chemotherapy without radiation avoids the possibility of decreased anal function due to radiation to the anal sphincter. In this study, sphincter preservation was achieved in 60.9% of patients, and no patient had to retain their ileostomy or undergo stoma construction after resection. There remains a need for a randomized clinical trial to assess the advantage of neoadjuvant chemotherapy compared with neoadjuvant CRT with regard to preserving anal sphincter function.

Tumor shrinkage due to neoadjuvant chemotherapy may increase the rate of complete resection. We previously reported the achievement of R0 resection in all patients who underwent neoadjuvant chemotherapy for locally advanced rectal cancer[1], and other trials also report R0 resections in almost all patients under these circumstances[3-5,8]. With neoadjuvant CRT, pCR rates range from 11.4% to 27.5%[2,8-18]. On the other hand, the pCR rate with neoadjuvant chemotherapy was 4.3% in our present trial, and rates range from 6.6% to 25% in prior studies[3-5,8]. Thus, pCR rates are higher with neoadjuvant CRT than neoadjuvant chemotherapy. However, the R0 resection rate was not worse with neoadjuvant chemotherapy than with neoadjuvant CRT. These data suggest that neoadjuvant chemotherapy is an acceptable treatment strategy for locally advanced rectal can-

### Table 5. Tumor Regression and Recurrence.

|                      | Total number | Recurrence | Local* | Distant lymph node | Lung | Liver |
|----------------------|--------------|------------|--------|--------------------|------|-------|
| Favorable tumor regression |              |            |        |                    |      |       |
| pCR                  | 1            | 0 (0%)     |        |                    |      |       |
| Near-pCR             | 4            | 0 (0%)     |        |                    |      |       |
| Suboptimal tumor regression | 18          | 6 (33%)    | 4      | 1                  | 1    | 1     |

* Include one duplication of Local and Distant Lymph node

### Table 6. Patients’ Demographics of Recurrence.

| ypStage | Adjuvant chemotherapy | Recurrence site          | Surgery for recurrence site |
|---------|-----------------------|--------------------------|----------------------------|
| I       | No                    | Local (Lateral LN) and Distant LN | Resection                 |
| II      | No                    | Local (anastomosis site)  | Resection                 |
| II      | CAPOX                 | Local (Lateral LN)        | Lateral LN dissection      |
| IIIA    | CAPOX                 | Liver                    | Resection                 |
| IIIA    | No                    | Lung                     | Resection                 |

LN: lymph node

**Discussion**

Figure 1. Progression-free survival and overall survival after enrollment.
Some evidence suggests that chemotherapy including an adequate dose of oxaliplatin before resection might reduce the rate of distant metastatic recurrence[19]. Postoperative adjuvant chemotherapy with oxaliplatin improves the prognosis of colon cancer patients. However, recent clinical studies have attempted to improve treatment outcomes in locally advanced rectal cancer by using neoadjuvant CRT including oxaliplatin and have not found a better prognosis than with conventional CRT[12,16]. Moreover, no clinical trial has demonstrated a prognostic advantage of adjuvant chemotherapy for rectal cancer. It is unclear why adjuvant chemotherapy that improves the prognosis of colon cancer patients would not be effective as adjuvant chemotherapy in rectal cancer. One possibility is that the completion rate of adjuvant chemotherapy after neoadjuvant CRT followed by TME was lower to reduce recurrence including distant metastasis[6]. Other possibility is that this difference may be related to the distinct gene expression of colorectal cancer according to tumor location[20,21].

With regard to prior studies of neoadjuvant chemotherapy for locally advanced rectal cancer, Schrag et al.[4] reported 4 year DFS of 84%, and Patel et al.[22] reported 41 month DFS of 61%. In our present study, the 5 year PFS was 70.0%. Our study differed from prior studies with regard to patient background and treatment. For example, all cases in Schrag’s trial had a T stage of T3, and Patel’s study had a higher rate of incomplete neoadjuvant chemotherapy treatment. Our present results indicate that pCR and near-pCR patients had an improved prognosis. There remains a need for a large randomized clinical trial to compare the long-term prognosis of locally advanced rectal cancer with neoadjuvant chemotherapy versus CRT.

The local recurrence rate was 17.4% (4/23), including one case of duplicates of distant lymph node recurrence. The local recurrence site was anastomosis site in one patient and lateral lymph node in three patients. The lateral lymph node dissection was not done in two out of three patients who suffered lateral lymph node recurrence. The CRT or the lateral lymph node dissection for the lower rectal cancer patients of stage II/III might be improve the local recurrence rate. On the other hand, the hematogenous metastasis including lung and liver recurrence might be low (8.7%, 2/23) in this study. The distant recurrence rate in the study of CRT for rectal cancer was ranged from 17% to 27%[11,23]. Neoadjuvant chemotherapy might improve the hemagogenous distant recurrence. Thus, neoadjuvant chemotherapy might be used to improve distant recurrence rate and CRT be used to improve local recurrence rate.

The present study has several limitations. As it was a single-arm trial with a small sample size, we could not compare neoadjuvant chemotherapy with standard therapy, and our results did not prove the effectiveness of neoadjuvant chemotherapy. Additionally, the adjuvant chemotherapy regimen was not regulated in this study.

In conclusion, here, we report the long-term results of CAPOX + BV as neoadjuvant chemotherapy, demonstrating a favorable prognosis. The local recurrence rate was high; however, the distant recurrence rate might be low. This study was a prospective single-arm clinical trial with a small sample size, and there remains a need for a larger clinical trial to verify the effectiveness of neoadjuvant chemotherapy for locally advanced rectal cancer.

Conflicts of Interest
There are no conflicts of interest.

Author Contributions
Contributions to the design of the work: JN, JH, SN, KI, MY, TK, MT, KY, TS, MU, TH, CM, TM, MI, YD, and MM
Contributions to the acquisition of data for the work: JN, JH, SN, KI, MY, TK, MT, KY, TS, MU, TH, CM, and TM
Contributions to analysis, and interpretation of data for the work: JN, JH, MU, TH, CM, and TM
Drafting the work or revising it: JN, JH, SN, KI, MY, TK, MT, KY, TS, MU, TH, CM, TM, MI, YD, and MM
Approval by Institutional Review Board (IRB)
Approval code of IRB: 15464
The name of the institution that granted the approval: Osaka University Hospital

References
1. Hasegawa J, Nishimura J, Mizushima T, et al. Neo-adjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol 2014 May; 73(5): 1079-87.
2. Nishimura J, Hasegawa J, Kato T, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. Cancer. Chemother Pharmacol 2018 Oct; 82(4): 707-16.
3. Fernandez-Martos C, Brown G, Estevan R, et al. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 phase II multicenter trial. Oncologist. 2014 Oct; 19(10): 1042-3.
4. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014 Feb; 32(6): 513-8.
5. Uehara K, Hiramatsu K, Maeda A, et al. Neoadjuvant oxaliplatin and 5-fluorouracil (CAPOX) as perioperative therapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013 Oct; 43(10): 964-71.
6. Sun Z, Gilmore B, Adam MA, et al. Adjuvant chemotherapy after preoperative chemoradiation improves survival in patients with locally advanced rectal cancer. Dis Colon Rectum. 2017 Oct; 60...
113

7. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005 May; 241(5): 829-36; discussion 836-8.

8. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016 Sep; 34(27): 3300-7.

9. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011 Jul; 29(20): 2773-80.

10. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep; 355(11): 1114-23.

11. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006 Oct; 93(10): 1215-23.

12. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012 Dec; 30(36): 4558-65.

13. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006 Oct; 24 (28): 4620-5.

14. Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014 Oct; 15(11): 1245-53.

15. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012 Nov; 30(31): 3827-33.

16. O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014 Jun; 32(18): 1927-34.

17. Rodel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul; 13(7): 679-87.

18. Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009 Nov; 27(31): 5124-30.

19. Colvin H, Mizushima T, Eguchi H, et al. Gastroenterological surgery in Japan: The past, the present and the future. Ann Gastroenterol Surg. 2017 Apr; 1(1): 5-10.

20. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 2005 Mar; 54(3): 374-84.

21. Gao XH, Yu GY, Gong HF, et al. Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. Sci Rep. 2017 Aug; 7(1): 7882.

22. Patel UB, Brown G, Machado I, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for Primary Rectal Cancer: longterm results from the GEMCAD 0801 trial. Ann Oncol. 2017 Feb; 28(2): 344-53.

23. Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug; 16(8): 979-89.